前沿速览017期| CAR-T治B淋 前沿览新知
01
不采取GVHD预防策略的CD7 CAR-T细胞疗法和异基因HSCT序贯方案
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
第一作者：Hu Y
N Engl J Med (IF=158.5). 2024 Apr 25;390(16):1467-1480.
全文网址：https://www.nejm.org/doi/10.1056/NEJMoa2313812?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
预测CAR-T细胞治疗大B细胞淋巴瘤结局的常规和新型 [(18)F]FDG PET/CT 特征
Conventional and novel [(18)F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
第一作者：Leithner D
J Hematol Oncol (IF=28.5). 2024 Apr 23;17(1):21.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035117/
03
Lisocabtagene maraleucel回输前用苯达莫司汀清淋的有效性和安全性
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucell
第一作者：Ghilardi G
J Hematol Oncol (IF=28.5). 2024 Apr 22;17(1):19.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11034069/
04
具有终末耗竭表型的TIM-3+ CD8 T细胞在血液瘤中保留效应功能
TIM-3(+) CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
第一作者：Minnie SA
Sci Immunol (IF=24.8). 2024 Apr 19;9(94):eadg1094.
全文网址：https://www.science.org/doi/10.1126/sciimmunol.adg1094?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
05
CAR-T细胞治疗大B细胞淋巴瘤的疗效不受既往双特异性抗体治疗的影响
Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma
第一作者：Crochet G
Blood (IF=20.3). 2024 Apr 24:blood.2024024526.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2024024526/515892/Efficacy-of-CAR-T-Cell-Therapy-is-Not-Impaired-by?redirectedFrom=fulltext
06
Axicabtagene Ciloleucel治疗大B细胞淋巴瘤的真实世界和临床试验结局（不同种族和民族）
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity
第一作者：Locke FL
Blood (IF=. 2024 Apr 18:blood.2023023447.
全文网址：https://ashpublications.org/blood/article/doi/10.1182/blood.2023023447/515777/Real-World-and-Clinical-Trial-Outcomes-in-Large-B
07
胎盘循环T细胞：一种新型的异体CAR-T细胞平台，与成人PBMC衍生的CAR-T细胞相比，它保留了T细胞干性，具有更有利的细胞因子谱和持久的疗效
Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T
第一作者：Ruggeri Barbaro N
J Immunother Cancer (IF=. 2024 Apr 29;12(4):e008656.
全文网址：https://jitc.bmj.com/content/12/4/e008656.long
08
在睡美人转座子系统中开发靶向CD19和CD20紧凑型双向启动子驱动的双CAR构建体
Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system
第一作者：Khaniya A
J Immunother Cancer (IF=10.9). 2024 Apr 27;12(4):e008555.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11057265/
09
在R/R LBCL中，CAR-T细胞治疗联合HDT/ASCT具有良好的临床疗效，还改善了CAR-T细胞行为
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
第一作者：Liu W
J Immunother Cancer (IF=10.9). 2024 Apr 16;12(4):e008857.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11029269/
10
早回输更获益：评估缩短vein-to-vein时间对接受CAR-T治疗的LBCL患者的终生影响
Don't keep me waiting: estimating the lifetime impact of reduced vein-to-vein time for CAR-T treated patients with LBCL
第一作者：Vadgama S
Blood Adv (IF=7.6). 2024 Apr 25:bloodadvances.2023012240.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023012240/515896/Don-t-keep-me-waiting-estimating-the-lifetime
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.5-6 valid until 2026.5
供稿与审核：临床开发与医学部